PLOD1 and hypogonadism: The time dependent SHBG and LH increase associated with lower cFT levels with no significant changes in TT levels observed in our patients might explain the higher prevalence of hypogonadism detected respect to a previous study, reporting hypogonadism in about one out of three patients under mitotane therapy (16).